INTRODUCTION
Ceramide is a potent lipid mediator of cell stress responses [1, 2] . Depending upon the agonist and cell type, cellular responses to ceramide often culminate in increased apoptosis, decreased proliferative potential or effects on cell differentiation. The molecular mechanisms by which ceramide may activate apoptotic signalling have identified critical roles for stress-activated protein kinases, caspases and changes in mitochondrial function [3] . The anti-proliferative effects of ceramide are mediated, at least in part, by inhibition of cyclin-dependent kinases [4] and decreased phosphorylation of the retinoblastoma tumour suppressor protein [5] . In contrast, the molecular mechanisms by which ceramide affects cell differentiation remain poorly defined.
The process of adipogenesis in 3T3-L1 preadipocytes has proved an excellent model system for identifying molecular mechanisms that regulate terminal cell differentiation [6] . Upon confluence, 3T3-L1 preadipocytes undergo cell cycle arrest and begin to up-regulate the expression of early markers of differentiation, such as lipoprotein lipase [7] . Post-confluent preadipocytes may then be induced to differentiate into cells possessing morphological and biochemical characteristics of mature adipocytes. Although complex, induction of adipogenesis in 3T3-L1 cells is controlled by several basic events. Addition of a cell differentiation ' cocktail ' leads to the down-regulation of Abbreviations used : C/EBP-α, -β and -δ, CCAAT-enhancer-binding protein-α, -β and -δ ; C 2 -ceramide, N-acetylsphingosine ; DIMF, differentiation ' cocktail ' containing dexamethasone, insulin, methylisobutylxanthine and fetal calf serum ; D-e-MAPP, D-(1S,2R)-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol ; DMEM, Dulbecco's modified Eagle's medium ; EMSA, electrophoretic mobility shift assay ; FCS, fetal calf serum ; IP, immunoprecipitation ; MAPK, mitogen-activated protein kinase ; PPARγ, peroxisome-proliferator-activated receptor γ ; STAT-1, signal transducer of transcription 1 ; TNF-α, tumour necrosis factor α. 1 To whom correspondence should be addressed (e-mail dobrowsky!ku.edu).
localization at 24 h. However, ceramide did not change the nuclear level of C\EBPβ after a period of 4 or 16 h, suggesting that it was not affecting nuclear import. CRM1 (more recently named ' exportin-1 ') is a nuclear membrane protein that regulates protein export from the nucleus by binding to a specific nuclear export sequence. Leptomycin B is an inhibitor of CRM1\ exportin-1, and reversed the ceramide-induced decrease in nuclear C\EBPβ at 24 h. Taken together, these data support the hypothesis that ceramide may inhibit adipogenesis, at least in part, by enhancing dephosphorylation and premature nuclear export of C\EBPβ at a time when its maximal transcriptional activity is required to drive adipogenesis.
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preadipocyte factor-1 [8] , calpain activation and a subsequent phase of mitotic clonal expansion [9, 10] . However, adipogenesis is dependent upon the co-ordinated expression of two classes of transcription factors : CCAAT-enhancer-binding proteins α, β and δ (C\EBPα, C\EBPβ, C\EBPδ) [11] and peroxisomeproliferator-activated receptor-γ (PPARγ) [12, 13] . The C\EBP family members are bZIP transcription factors that possess a leucine zipper and a basic DNA-binding domain in their C-terminal region, and an N-terminal transactivation domain [14] . Following hormonal induction of 3T3-L1 cells, C\EBPβ and C\EBPδ are rapidly induced and transported to the nucleus [15] . Moreover, phosphorylation of C\EBPβ correlates with its ability to bind DNA and competency to transactivate downstream genes necessary to induce adipogenesis [15, 16] . The acquisition of DNA-binding ability also correlates with the association of C\EBPβ with centromeres and the entry of the quiescent preadipocytes into a phase of mitotic clonal expansion [15] . Although the exact role of clonal expansion in regulating adipogenesis of 3T3-L1 cells is uncertain [17] , the activity of C\EBPβ and C\EBPδ is required for adipogenesis of 3T3-L1 cells [18] and the development in i o of white and brown adipose tissue [19] .
C\EBPβ is maximally expressed within the first 48 h following hormonal stimulation, and induces the expression of C\EBPα and PPARγ, before its own expression begins to diminish rapidly [11, 20] . By 72 h post-stimulation, C\EBPα and PPARγ are both highly expressed. The continued expression of C\EBPα and PPARγ is critical for inducing and maintaining the expression of adipocyte-specific genes, such as adipisin and proteins related to adipocyte function, i.e. phosphoenolpyruvate carboxykinase, acyl-CoA synthase, stearoyl-CoA desaturase, etc. [7] .
In the present study, we describe the novel finding that increases in endogenous ceramide, or addition of a cell-permeant ceramide analogue to hormonally stimulated 3T3-L1 cells, induced a partial block of mitotic clonal expansion, potently inhibited the expression of C\EBPα and PPARγ, and blocked the development of the mature adipocyte phenotype. Although ceramide had no effect on the total cellular expression of C\EBPβ, it inhibited the nuclear localization of C\EBPβ at 24 h after hormonal stimulation of the 3T3-L1 cells. Decreased nuclear localization of C\EBPβ correlated with decreased phosphorylation, DNA binding and its ability to transactivate a reporter construct in differentiating 3T3-L1 cells. Interestingly, an inhibitor of nuclear export, leptomycin B, reversed the ceramideinduced decrease in nuclear levels of C\EBPβ, suggesting that the block to adipogenesis by ceramide may arise from a premature export of dephosphorylated forms of C\EBPβ from the nucleus. Taken together, our results provide the first evidence that ceramide may act as a negative regulator of adipogenesis ; in part, by inhibiting the transactivating capacity of C\EBPβ. 
EXPERIMENTAL Materials

.). N-[$H]Acetylsphingosine ([$H]C
# -ceramide ; 25 mCi\mmol) was kindly given by Dr A. Bielawska (Medical University of South Carolina, Charleston, SC, U.S.A.). C # -ceramide and -and -(1S,2R)-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (-e-and -e-MAPP respectively) were products of Matreya (Pleasant Gap, PA, U.S.A.). Dexamethasone, insulin, methylisobutylxanthine, Oil Red O and leptomycin B were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). The dual reporter luciferase assay was from Promega (Madison, WI, U.S.A.). Polyclonal antibodies raised against C\EBPβ, C\EBPα and PPARγ were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Monoclonal antibody against nucleoporin was from B&D Signal Transduction Laboratories (San Diego, CA, U.S.A.) ; AlexaFluor 488 and 568 secondary antibodies were purchased from Molecular Probes (Eugene, OR, U.S.A). cDNAs for pMEX-C\EBPβ and the firefly luciferase reporter constructs, (DE-I) % (k35Alb)LUC and (k35Alb)LUC were kindly given by Dr Simon Williams, and have been described previously [21] .
Cell lines and differentiation protocol
3T3-L1 preadipocytes were subcultured in Dulbecco's modified Eagle's medium (DMEM) containing 10 % (v\v) calf serum. Adipogenesis was induced using published protocols [20, 22] . The cells were grown to confluence and maintained in DMEM\10 % (v\v) calf serum for 2 days before the addition of the differentiation cocktail. The cells were induced to differentiate on day 0 by the addition of DMEM containing 2 µM dexamethasone, 2 µg\ml insulin, 0.5 mM methylisobutylxanthine and 10 % (v\v) fetal calf serum (FCS). We refer to this differentiation cocktail as ' DIMF '. After 2 days, the medium was replaced with DMEM containing 10 % FCS supplemented with 2 µg\ml insulin. Every 2 days, the medium was replaced with DMEM containing 10 % (v\v) FCS without additional insulin. HEK-293 cells were maintained in DMEM containing 10 % calf serum.
Ceramide treatment of 3T3-L1 cells and assessment of adipose phenotype
At the time of addition of DIMF, 3T3-L1 preadipocytes were cotreated with either vehicle [0.1 % (v\v) DMSO] or the indicated concentration of C # -ceramide. Similar to protocols for inhibiting adipogenesis with retinoic acid [20] , the C # -ceramide remained present during the first 2 days of differentiation and each subsequent media change was supplemented with vehicle or 20 µM C # -ceramide. In experiments using \-e-MAPP, the cells were co-treated at the time of DIMF addition and the drugs resupplemented with each medium change. After 7 days of differentiation, the development of the mature adipose phenotype was assessed by the formation of lipid-laden droplets using the triacylglycerol-binding dye Oil Red O [20] .
Immunoblot analysis and immunoprecipitation (IP)
On the indicated day, the cells were scraped into lysis buffer [60 mM Tris\HCl (pH 8.0)\1 % (w\v) SDS], boiled for 2 min, vortex-mixed, and boiled again for 5 min. An equal amount of protein from each day's lysate was subjected to SDS\PAGE using 10 % (w\v) acrylamide gels. Proteins were transferred to nitrocellulose membranes, and an equal loading was verified by staining the membrane with 0.5 % Ponceau S in 5 % (w\v) trichloroacetic acid. The membranes were probed with the indicated primary antibodies and a horseradish-peroxidaseconjugated secondary antibody. Immunoreactive proteins were visualized using the Amersham ECL2 reagents as described by the manufacturer. For IP, the cells were scraped into IP buffer [50 mM Tris\HCl (pH 7.4)\150 mM NaCl\1 mM EDTA\1 % (v\v) Nonidet P40\0.5 mM sodium orthovanadate\40 mM NaF\10 mM β-glycerophosphate\Complete protease inhibitors (Roche Diagnostics, Mannheim, Germany] and C\EBPβ was immunoprecipitated using 4 µg of primary antibody\mg of cell lysate for 2 h at 4 mC. Immune complexes were formed by the addition of Protein A-Sepharose for 1 h at 4 mC ; the isolated immune complexes were then washed three times with IP buffer, and subjected to SDS\PAGE.
Transient transfections and dual luciferase assays
A dual luciferase assay was used to examine the effect of ceramide on C\EBPβ-dependent transactivation. The assay permits analysis of the effector-driven transactivation of the reporter construct containing firefly luciferase and the concomitant assessment of transfection efficiency by monitoring the constitutive activity of luciferase from the sea pansy Renilla reniformis. 3T3-L1 preadipocytes were grown to confluence and transiently co-transfected with C\EBPβ cDNA, the reporter construct (DE-I) % (k35 Alb)LUC and the control reporter plasmid pRL, which contains cDNA encoding luciferase from R. reniformis. (k35 Alb)LUC was used in separate transfections as a negative control, since it lacks the four DE-I C\EBPβ binding sites. The cells were transfected with 2 µg of total DNA using AMINE TM . The proportions of C\EBPβ cDNA : firefly luciferase reporter plasmid :sea pansy luciferase reporter plasmid were 50 : 50 : 1. After transfection (5 h), the cells were treated with DIMF in the absence or presence of C # -ceramide, and cell lysates were prepared 24 h later. HEK-293 cells were transfected similarly, and after 5 h these were treated with vehicle or the indicated concentration of C # -ceramide. Luciferase activity was determined 24 h after the addition of C # -ceramide using the Dual Luciferase Assay Kit (Promega).
Nuclear extraction and electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared essentially as described previously [23] . 3T3-L1 preadipocytes were washed once in ice-cold PBS, treated with trypsin and collected by centrifugation at 250 g for 10 min at 4 mC. The supernatant was removed, and the cell pellet was re-suspended in 5 vol. of Buffer A [10 mM Hepes (pH 7.9)\1.5 mM MgCl # \10 mM KCl\0.5 mM dithiothreitol\ 0.5 mM PMSF]. The samples were incubated on ice for 10 min, and centrifuged as described above. The pellet was re-suspended in 3 vol. of Buffer A, Nonidet P40 was added to a final concentration of 0.05 % (v\v), and the samples were homogenized to release the nuclei. The nuclei were pelleted by centrifugation at 250 g for 10 min at 4 mC, re-suspended with an equal volume of Buffer C [5 mM Hepes (pH 7.9)\26 % (v\v) glycerol\1.5 mM MgCl # \0.2 mM EDTA\0.5 mM dithiothreitol\0.5 mM PMSF], and NaCl was added to a final concentration of 300 mM. The samples were mixed well, incubated on ice for 30 min, and centrifuged at 24 000 g for 20 min at 4 mC. The supernatant was quickly frozen in a solid-CO # \ethanol bath, and stored at k80 mC until use. The EMSA was performed using the Geneka C\EBP-β NuShift kit, as described in the manufacturer's protocol. Protein-DNA complexes were resolved at 200 V on a prerun 6 % non-denaturing Tris\borate\EDTA (' TBE ') gel (1iTBE l 45 mM Tris\borate\1 mM EDTA) at 4 mC. The gel was dried, and the bands were visualized by autoradiography.
Immunofluorescence analysis
3T3-L1 preadipocytes were grown on poly(-lysine)-coated coverslips. After treatment, coverslips were gently washed three times with ice-cold PBS, and fixed with 300 µl of PBS containing 2 % (w\v) paraformaldehyde, 3 % sucrose and 0.02 % sodium azide for 10 min at 25 mC. The coverslips were again washed three times in PBS, and blocked with 5 % (w\v) BSA in PBS for 10 min at 25 mC. After washing three times in PBS, the cells were permeabilized with 0.2 % (v\v) Triton X-100 in PBS for 5 min at 25 mC. The coverslips were again washed three times in PBS, and then incubated in 5 % BSA in PBS containing the indicated primary antibody for 30 min at 25 mC. The coverslips were washed six times in PBS, and incubated in 5 % BSA in PBS containing either AlexaFluor 488 (green) goat anti-rabbit or AlexaFluor 568 (red) rabbit anti-mouse secondary antibodies for 30 min at 25 mC in the dark. After washing six times in PBS, antifade solution (Molecular Probes) was added, and the coverslips were mounted on glass slides. Images were captured on a BioRad MRC 1000 confocal microscope.
RESULTS C 2 -ceramide inhibits adipogenesis
C # -ceramide is a cell-permeant form of ceramide that has been used extensively to identify ceramide as a mediator of numerous biological responses [24] . To determine the effect of ceramide on adipogenesis, 3T3-L1 preadipocytes were co-treated with vehicle or C # -ceramide at the time of induction (day 0) with DIMF (see the Experimental section). At 7 days after the initiation of differentiation, the cells were fixed, and the lipid droplets were stained with Oil Red O. Figure 1 (A) shows that DIMF induced extensive differentiation of the control cells to mature adipocytes, as shown by the rounded morphology full of red-stained lipid droplets [6] . In contrast, simultaneous addition of 40-50 µM C # -ceramide with DIMF at day 0 strongly decreased the level of differentiated cells at day 7 ( Figures 1B and 1C) . The inhibitory effect of ceramide on adipogenesis was not limited to focal fields of cells, since macroscopic inspection of the plates of Oil Red Ostained cells revealed extensive inhibition of cell differentiation ( Figure 1D ). C # -ceramide induces apoptosis in many cell systems at the concentrations necessary to inhibit adipogenesis. However, we observed no cell death in the C # -ceramide-treated preadipocytes, indicating that the block to differentiation is not related to fewer surviving cells. Indeed, C # -ceramide can be extensively bound by the high concentration of serum proteins present in the differentiation cocktail [25] . To provide a more accurate estimate of the effective concentration of C # -ceramide required to inhibit adipogenesis, we examined the uptake of 50 µM [$H]C # -ceramide (tritium label in sphingoid backbone) by the cells. Preadipocytes were co-treated with DIMF and 50 µM [$H]C # -ceramide, and the amount of cell-associated radiolabel present was determined at intervals up to 12 h. The uptake of [$H]C # -ceramide was rapid, and reached a steady-state level within 2 h ( Table 1 ). The cells incorporated approx. 20 % of the radiolabel at the steady state, suggesting that the effective concentration for inhibiting adipogenesis of the 3T3-L1 cells is approx. 8-10 µM C # -ceramide. Importantly, the cell-associated radioactivity at all time points was primarily [$H]C # -ceramide, and not a metabolite (results not shown). In this regard, other lipids, such as sphingosine, sphingomyelin and phosphatidylcholine, had no effect on adipogenesis (results not shown). Moreover, addition of 50 µM C # -dihydroceramide at the time of differentiation was completely ineffective at inhibiting development of the mature adipose phenotype, on the basis of the extent of staining with Oil Red O (see below). C # -dihydroceramide lacks the 4,5-trans-double bond found in ceramide, and, in most cell systems, is unable to mimic the biological responses induced by C # -ceramide. Taken together, these data suggest that exogenous C # -ceramide is a potent lipid inhibitor of adipogenesis, similar to retinoic acid [20] and prostaglandin F2α [26] .
C 2 -ceramide inhibits expression of C/EBP-α and PPAR-γ
The expression of C\EBP-α and PPAR-γ is necessary for terminal differentiation of adipocytes [7] . Therefore the block to adipogenesis by C # -ceramide suggested that the expression and\or activity of these transcription factors might be affected by ceramide. Similar to many previous reports, DIMF induced a significant production of C\EBPα and PPARγ expression, beginning 3 days after the induction of differentiation (Figure 2) . However, C # -ceramide strongly decreased the expression of both C\EBPα and PPARγ (Figure 2A ). The effect of C # -ceramide on the expression of C\EBPα on day 3 following hormonal stimulation was dose-dependent ( Figure 2B , upper panel) and specific, since 50 µM C # -dihydroceramide could not inhibit C\EBP-α expression ( Figure 2B, lower panel) .
To examine the possibility that the inhibition of C\EBPα and PPARγ expression by C # -ceramide was purely a pharmacological effect, we increased the levels of intracellular ceramide with the alkaline ceramidase inhibitor, -e-MAPP [27] . Preadipocytes were co-treated with -e-MAPP and DIMF on day 0, the medium was replaced after 2 days (plus fresh -e-MAPP), and cell lysates were prepared on day 3 following DIMF treatment. Treatment of preadipocytes with 50-70 µM -e-MAPP increased intracellular ceramide levels up to 1.7-fold by 24 h (results not shown). Similar to exogenous C # -ceramide, -e-MAPP also blocked the expression of C\EBP-α on day 3 after differentiation 
H]C 2 -ceramide uptake by preadipocytes
Post-confluent preadipocytes were co-treated with DIMF and 50 µM [ 3 H]C 2 -ceramide (100 000 c.p.m./dish). At the indicated time, the medium was aspirated (after extracting an aliquot), and the cells were washed twice with ice-cold PBS. The cells were scraped into PBS, homogenized and an aliquot was used to determine the amount of cell-associated radiolabel. ( Figure 3) . To determine the specificity of -e-MAPP on inhibiting the expression of C\EBP-α, the cells were treated with the inactive enantiomer, -e-MAPP [27] . Not surprisingly, -e-MAPP neither increased ceramide levels nor inhibited the expression of C\EBP-α (Figure 3 ). These data support the notion that C # -ceramide effectively mimics the effect of endogenous ceramides.
Preliminary studies indicated that addition of C # -ceramide more than 48 h after differentiation did not block expression of C\EBPα. To identify the temporal ' window ' where ceramide was most effective at inducing downstream changes in the expression of C\EBPα, C # -ceramide was added simultaneously with DIMF (0 h), or 2, 4, 6, 8 or 24 h after the addition of DIMF (Figure 4) . Cell lysates were then prepared on day 3 of differentiation to examine the expression of C\EBPα. The magnitude of C\EBPα expression at day 3 from cells treated with DIMF plus 0.1 % (v\v) DMSO was used as the control in these experiments (Figure 4 , ' Control '). The expression of C\EBPα was strongly blocked when C # -ceramide was added within the first 4 h after the induction of differentiation (Figure 4 , lanes pertaining to 0-4 h). However, adding C # -ceramide later than 4 h after DIMF resulted in a gradual loss in the block to C\EBPα expression. If ceramide was added 24 h following DIMF, it was ineffective at inhibiting the expression of C\EBPα. These results suggest that C # -ceramide is affecting an early event in adipogenesis.
Ceramide inhibits DNA binding and C/EBPβ-mediated transcriptional activation
An early event in adipogenesis of 3T3-L1 preadipocytes is the rapid up-regulation and nuclear translocation of C\EBPβ [15] . Moreover, C\EBPβ is known to undergo extensive phosphorylation by various kinases, such as p42\44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase C and Ca# + \calmodulin protein kinase [14, 28] . Since the expression of C\EBPβ is necessary for mediating transcription of C\EBPα and PPARγ [20] , we examined the effect of ceramide on the expression, phosphorylation and activity of this transcription factor. C # -ceramide had no effect on the total cellular expression of C\EBPβ ( Figure 5 , lower panel), but had a biphasic effect on its phosphorylation. C # -ceramide slightly enhanced phosphorylation of C\EBPβ at 4 and 8 h, but strongly decreased its phosphorylation at 24-48 h ( Figure 5, upper panel) . After normalizing for C\EBPβ expression, ceramide decreased its phosphorylation by 57.8p1.3 % and 67.4p0.1 % (n l 3) at 24 and 48 h respectively. Consistent with a previous report that phosphorylation of C\EBPβ at 24-48 h is critical for it to become competent to bind DNA and induce expression of C\EBPα [15] , the ceramide-induced decrease in C\EBPβ phosphorylation at 24 h correlated with a decrease in its DNA-
Figure 4 C 2 -ceramide is maximally effective at decreasing C/EBPα expression within 4 h after the induction of differentiation
Post-confluent preadipocytes were treated with DIMF in the absence of ceramide and allowed to differentiate for 3 days. Cell lysates were prepared, and the expression of C/EBPα was analysed by immunoblot analysis (lane 1, Control). To determine the time course for inhibition of C/EBPα expression by ceramide, 50 µM C 2 -ceramide was added simultaneously with DIMF (time 0) or at the indicated time after the addition of DIMF. The cells were differentiated for 3 days, cell lysates were prepared and the expression of C/EBPα was determined by immunoblot analysis. The extent of C 2 -ceramide-induced changes in C/EBPα was semiquantified by densitometry, expressed as percentages of the control (lane 1), and is featured below each lane. Data shown are from a representative experiment performed three times with similar results.
Figure 5 C 2 -ceramide decreases the phosphorylation of C/EBPβ, but not its total cellular expression
Post-confluent preadipocytes were labelled with 0.2 mCi/ml [ 32 P]P i overnight, and the medium was supplemented with DIMF in the presence or absence of 50 µM C 2 -ceramide. At the indicated time following DIMF addition, the cells were scraped into IP buffer and C/EBPβ was immunoprecipitated. The isolated proteins were resolved by SDS/PAGE, transferred to nitrocellulose and the presence of [ 32 P]C/EBPβ was determined using a PhosphorImager (upper panels). The total levels of C/EBPβ were then determined by immunoblot analysis (lower panels). . Although C\EBPβ appears to be the major component of these DNA-protein complexes, the remaining unshifted band is likely to be due to the presence of some C\EBPδ in the complexes, as reported previously [15] . Lastly, addition of C # -ceramide directly to a reaction mix containing recombinant C\EBPβ and the labelled oligonucleotide probe had no effect on C\EBPβ binding (results not shown). These results argue against ceramide directly interfering with the ability of C\EBPβ to bind to the probe.
To examine whether the ceramide-induced decrease in the DNA-binding ability of C\EBPβ correlated with decreased transcriptional activity, confluent 3T3-L1 preadipocytes were transiently transfected with the reporter construct (DE-I) % (k35 Alb)LUC. Following transfection (5 h), the cells were co-treated with DIMF plus vehicle, or 30-40 µM C # -ceramide ; the cells
Figure 6 C 2 -ceramide decreases C/EBPβ-mediated DNA binding
Post-confluent preadipocytes were co-treated with DIMF and 50 µM C 2 -ceramide. After 24 h, nuclear extracts were prepared and an EMSA for C/EBPβ DNA binding was conducted using 10 µg of each nuclear extract and reagents provided in the NuShift kit. A positive control for C/EBPβ binding was performed using recombinant C/EBPβ (second lane from the left).
Figure 7 C 2 -ceramide inhibits C/EBPβ-mediated transcription
Post-confluent preadipocytes were transiently co-transfected with (A) pCDNA or (B) C/EBPβ and the two luciferase reporter constructs. After transfection (5 h), the cells were co-treated with DIMF in the absence or presence of C 2 -ceramide. Dual luciferase activity was measured 24 h later as described in the Experimental section. The asterisk indicates statistical significance (P 0.05), as determined using a one-way ANOVA and a Student-Newman-Keuls post-hoc test. Data shown are the meanspS.E.M. from a representative experiment performed in quadruplicate. The experiment was repeated four times with comparable results.
were exposed to less C # -ceramide, since the transfection protocol rendered the cells sensitive to higher lipid concentrations, resulting in cell death. After differentiation (24 h), cell lysates were prepared, and dual luciferase activity was measured. C # -ceramide-treated preadipocytes co-transfected with the reporter construct (DE-I) % (k35 Alb)LUC and pRL showed a statistically significant 20-30 % decrease in transactivation from the DE-I binding sites ( Figure 7A ). Since little transactivation was apparent using the (k35 Alb)LUC construct in the absence or presence of ceramide, fold activation was calculated on the basis of the very basal level of activity from this construct. To provide further support that C # -ceramide was blocking transactivation of luciferase from the DE-I binding sites, preadipocytes were co-transfected with C\EBPβ cDNA in the presence of (DE-I) % (k35 Alb)LUC and pRL. If C # -ceramide was inhibiting the transactivating capacity of C\EBPβ, then this inhibition should be more apparent in cells further overexpressing C\EBPβ. Preadipocytes transfected with exogenous C\EBPβ and treated with DIMF in the absence of C # -ceramide showed a 5-fold increase in baseline transactivation from (DE-I) % (k35 Alb)LUC ( Figure 7B ). However, treatment with 30-40 µM C # -ceramide still significantly diminished transactivation by up to 40 % from the (DE-I) % (k35 Alb)LUC reporter. Taken together, these results suggest that ceramide, similar to retinoic acid [20] , might block adipogenesis at the level of C\EBPβ.
To examine whether the effect of C # -ceramide on inhibiting transactivation by C\EBPβ was a cell-specific phenomenon, we attempted to reconstitute the response in cells that do not endogenously express C\EBPβ. Immunoblot analysis of wholecell lysates from HEK-293 cells revealed a very low level of specific immunoreactivity for the presence of endogenous C\ EBPβ ( Figure 8A ). Therefore the HEK-293 cells were transiently co-transfected with C\EBPβ cDNA and the various reporter plasmids. After transfection (5 h), the cells were treated with
Figure 9 C 2 -ceramide specifically decreases the nuclear localization of C/EBPβ
(A) Nuclear extracts were prepared from post-confluent preadipocytes co-treated with DIMF and 50 µM C 2 -ceramide (upper panel) or C 2 -dihydroceramide (lower panel). The nuclear proteins were subjected to SDS/PAGE, transferred to nitrocellulose, and the level of C/EBPβ was determined by immunoblot analysis. The effect of C 2 -dihydroceramide on nuclear localization of C/EBPβ was determined only at 24 h. (B) Preadipocytes were grown to 2 days post-confluence on coverslips and treated with DIMF in the absence (Control) or presence of 50 µM C 2 -ceramide. The cells were co-stained with an antibody raised against C/EBPβ (green ; AlexaFluor 488 anti-rabbit IgG secondary antibody) and the nuclear membrane marker protein, nucleoporin (red ; AlexaFluor 568 antimouse IgG secondary antibody). The fluorescent signals were analysed by confocal microscopy, and the green and red signals from the same focal fields were merged to clearly demarcate the nucleus. Cells stained only with the AlexaFluor 488 or 568 secondary antibodies showed no specific immunofluorescence (results not shown). (C) Post-confluent preadipocytes were co-treated with DIMF and 50 µM C 2 -ceramide at the indicated times, and nuclear extracts were prepared. The nuclear proteins were subjected to SDS/PAGE, transferred on to nitrocellulose and the level of STAT-1 was determined by immunoblot analysis. (D) Preadipocytes were grown to 2 days post-confluence on coverslips, and treated with DIMF in the absence or presence of 50 µM C 2 -ceramide. The cells were co-stained with an antibody against STAT-1 (green) and the nuclear membrane marker protein, nucleoporin (red).
C # -ceramide in 10 % (v\v) FCS, and luciferase activity was determined after an additional 24 h. C # -ceramide caused a significant dose-dependent inhibition of C\EBPβ-mediated transcription in the HEK-293 cells (Figure 8B ), which proved less susceptible to higher concentrations of C # -ceramide following the transfection protocol. The decreased extent of transcription was not due to differences in the expression of C\EBPβ ( Figure  8A ) or to ceramide-induced cell death, since no loss of cell
Figure 10 Leptomycin B reverses the C 2 -ceramide-induced decrease in the in vivo nuclear localization of C/EBPβ
Preadipocytes were grown on coverslips and at 2 days post-confluence were treated with DIMF in the absence (A, C and E) or presence (B, D and F) of 50 µM C 2 -ceramide for the indicated times. To examine the effect of leptomycin B on the nuclear localization of C/EBPβ at 24 h, the cells were treated with 10-15 ng/ml leptomycin B plus DIMF in the absence (G and I) or presence (H and J) of 50 µM C 2 -ceramide for 24 h. All cells were co-stained with an antibody against C/EBPβ (green ; AlexaFluor 488 anti-rabbit IgG secondary antibody) and the nuclear membrane marker protein, nucleoporin (red ; AlexaFluor 568 anti-mouse IgG secondary antibody). The fluorescent signals were analysed by confocal microscopy, and the green and red signals from the same focal fields were merged so that the nuclear localization of C/EBPβ can be clearly demarcated by the staining of the nuclear membrane with nucleoporin.
viability was observed between control and ceramide-treated cells. Importantly, no luciferase activity was observed in the absence of C\EBPβ expression (results not shown). These data strongly support the notion that the ability of C # -ceramide to inhibit the transactivating capacity of C\EBPβ is not necessarily limited to the context of C\EBPβ expression during adipogenesis.
Ceramide decreases nuclear levels of C/EBPβ and enhances nuclear export of C/EBPβ
The differentiation of 3T3-L1 cells induces a rapid expression of C\EBPβ and, within 4 h, the total cellular pool is localized to the nucleus, where its level remains steady for approx. 48 h [15] . Since ceramide did not decrease the total cellular level of C\EBPβ, but did decrease its phosphorylation, DNA binding and ability to promote transcription, it is possible that changes in nuclear levels of C\EBPβ may account for these effects. To address this issue, cells were treated with DIMF in the absence and presence of C # -ceramide, nuclear extracts were prepared and C\EBPβ levels were determined by immunoblot analysis. Ceramide slightly increased the nuclear levels of C\EBPβ at 4 h but, after 24 h of treatment, its nuclear level was strongly decreased relative to control cells ( Figure 9A, upper panel) . The ceramide-induced decrease in the nuclear localization of C\EBPβ was specific, since treating the cells with C # -dihydroceramide had no effect on its nuclear localization ( Figure 9A, bottom panel) . This result is very consistent with the lack of effect of C # -dihydroceramide on inhibiting the expression of C\EBPα.
To provide a more accurate in i o measure of the effect of ceramide on the nuclear localization of C\EBPβ, indirect immunofluorescence and confocal microscopy was performed. As reported previously [15] , DIMF induced an intense punctate nuclear staining of C\EBPβ ( Figure 9B ). In agreement with the immunoblot results, C # -ceramide strongly decreased the intense nuclear localization for C\EBPβ and induced a more diffuse cytosolic staining at 24 h ( Figure 9B ). Importantly, ceramide did not decrease the nuclear localization in i o of an unrelated transcription factor, signal transducer and activator of transcription 1 (STAT-1 ; Figures 9C and 9D) , suggesting that the lipid was not non-specifically disrupting general nuclear trafficking. C # -ceramide may decrease nuclear levels of C\EBPβ by blocking import, increasing export or by enhancing nuclear degradation of the protein. In agreement with immunoblot analysis for the presence of C\EBPβ from nuclear extracts, C # -ceramide did not alter the nuclear accumulation of C\EBPβ after a period of 4 and 16 h, when analysed by indirect immunofluorescence ( Figure 10 , panels A-D, the green signal). However, ceramide again induced a significant loss of C\EBPβ from the nucleus at 24 h ( Figure 10 , panels E and F). These results suggested that ceramide was not inhibiting the nuclear import of C\EBPβ. Alternatively, the rather abrupt decrease in nuclear levels of C\EBPβ occurring between 16-24 h raised the possibility that changes in the rate of nuclear export may occur. Nuclear export can be regulated by the interaction of proteins containing a specific leucine-rich nuclear export sequence with CRM1\ exportin 1 [29] . Leptomycin B inhibits nuclear export by blocking the interaction of proteins containing a nuclear export sequence with CRM1\exportin 1 [30, 31] . Treatment of preadipocytes with 10-15 ng\ml leptomycin B reversed the ceramide-induced decrease in the nuclear levels of C\EBPβ at 24 h (Figure 10 , panels H and J), but had no effect on the nuclear level of C\EBPβ in control cells (Figure 10 , panels G and I). Collectively, these results provide a strong temporal correlation that ceramide may block adipogenesis by decreasing phosphorylation of C\EBPβ and enhancing its nuclear export at a time when the maximal transcriptional activity of this protein is required to drive adipogenesis [15] .
DISCUSSION
The cellular response to ceramide is quite variable, and is likely to be dependent upon cell type, developmental stage and the magnitude and kinetics of the ceramide flux [1] . Although the role of ceramide is poorly defined with respect to adipocyte development and function, our results suggest that elevation of endogenous ceramide levels is sufficient to block adipogenesis. However, these data do not address the necessity\sufficiency of ceramide as a physiological regulator of adipogenesis. Treatment of the cells with -e-MAPP increased endogenous ceramide levels approx. 1.7-fold, similar to levels induced by numerous ligands, such as interferon-γ, interleukin-1β and tumour necrosis factor α (TNF-α) [1] , which inhibit adipogenesis [32, 33] . These results raise the possibility that ceramide production may be sufficient to mediate the inhibitory effects of these ligands on adipogenesis. On the other hand, once adipogenesis is complete, ceramide may contribute to, but not be sufficient to mimic, some of the metabolic effects exerted by cytokines on mature adipocytes. For example, addition of 50 µM C # -ceramide or elevation of endogenous ceramide with a glucosylceramide synthase inhibitor was not sufficient to inhibit insulin receptor phosphorylation [34] . In contrast, ceramide production was necessary for the effect of TNFα in inhibiting insulin receptor phosphorylation, since partial inhibition of ceramide production reversed the block to insulin receptor phosphorylation by TNFα [34] . Lastly, adipocytes may also affect ceramide metabolism. In obese animals, the release of free fatty acids from triacylglycerol stores in adipocytes may accelerate ceramide synthesis de no o in pancreatic islet cells, leading to apoptosis and decreased insulin production [35] . Taken together, these results suggest that ceramide may be important in the regulation of adipocyte differentiation and function, and contribute to the development of diabetes in the obese. Ceramide is not the first lipid shown to inhibit adipogenesis of 3T3-L1 cells. Indeed, retinoic acid [36] and prostaglandin F2α [26] both inhibit adipocyte differentiation. Since prostaglandin F2α inhibits adipogenesis via phosphorylation and inactivation of PPARγ [26] , its mechanism is distinct from ceramide, which blocks PPARγ expression. Similar to ceramide, retinoic acid partially blocks mitotic clonal expansion, does not affect expression of endogenous C\EBPβ and inhibits C\EBPβ-mediated transcription [20, 22] . In contrast with ceramide, retinoic acid can effectively inhibit adipogenesis when added up to 48 h after hormonal induction [22, 36] . Although retinoic acid may increase ceramide levels in certain cells [37] , molecular data have strongly suggested that the interaction of the liganded retinoic acid receptor with C\EBPβ mediates the block to transcription and inhibits adipogenesis [20] . Ceramide is not known to interact with nuclear hormone receptors for retinoids, and retinoic acid has not been demonstrated to decrease the phosphorylation and nuclear localization of C\EBPβ. Thus the mechanisms by which retinoic acid and ceramide inhibit adipogenesis may be fundamentally different, but converge upon the regulation of C\EBPβ.
Recent data supports the hypothesis that the phosphorylation of C\EBPβ occurs concomitantly with the acquisition of DNAbinding ability and, presumably, increased transcriptional activity towards promoters for genes such as C\EBPα [15] . Indeed, treatment of nuclear extracts from hormonally stimulated preadipocytes with alkaline phosphatase decreased the DNA-binding ability of C\EBPβ [15] . These observations correlate very well with the effect of ceramide on decreasing the phosphorylation of C\EBPβ and diminishing its DNA-binding ability and transactivation potential at 24 h. Moreover, our data on the punctate nuclear staining of C\EBPβ agree with previous results indicating that it co-localizes to centromeres, and that this localization may have functional consequences in controlling mitotic clonal expansion [15] . Our data would be consistent with this hypothesis, since ceramide partially blocked clonal expansion at 24-48 h (20-60 % ; results not shown), which also correlates with the decreased phosphorylation of C\EBPβ and its loss of nuclear localization. Since C\EBPβ is phosphorylated on multiple sites, it will be necessary to identify the ceramide-inhibited kinase(s) or ceramide-activated phosphatases involved in regulating C\EBPβ to determine whether changes in C\EBPβ phosphorylation are a cause or consequence of increased nuclear export. However, we observed that ceramide did not inhibit p42\p44 MAPK or p38 MAPK, both of which may phosphorylate C\EBPβ.
A novel and unexpected result from these studies is that ceramide specifically induced a significant change in the nuclear localization of C\EBPβ at 24 h after hormonal induction of the preadipocytes. Indeed, C # -dihydroceramide had little effect on the nuclear pool of C\EBPβ. The loss of nuclear C\EBPβ could result from decreased import or enhanced export. In our opinion, several pieces of evidence are supportive of the notion that enhanced export is a more probable explanation, since : (i) the levels of nuclear C\EBPβ were similar between ceramide-treated and control cells at 4 h and 16 h after hormonal induction ; (ii) the total cellular levels of C\EBPβ did not change between ceramide-treated and control cells, suggesting that increased degradation did not account for the loss of C\EBPβ ; and (iii) the ceramide-induced loss of nuclear C\EBPβ was reversed by treatment of the cells with leptomycin B. If enhanced nuclear export of C\EBPβ was responsible for the ceramide-induced decrease in the expression of C\EBPα, then leptomycin B might be expected to reverse this effect. Unfortunately, treatment of preadipocytes with leptomycin B alone strongly blocked the expression of C\EBPα, suggesting that the nucleocytoplasmic shuttling of various transcription factors may be critical to adipogenesis. Thus, at this point, we cannot determine the exact contribution of the enhanced nuclear export of C\EBPβ to the ceramide-induced block to adipogenesis. Similar to our results, leptomycin B also blocked the nuclear export of C\EBPβ from hepatocytes stimulated with TNFα, leading to decreased transcription of the albumin gene [31] . Chojkier and co-workers noted the presence of a putative consensus sequence for nuclear export within the leucine zipper region of C\EBPβ [31] . Since leptomycin B inhibits the interaction of proteins containing a nuclear export sequence with CRM1\exportin 1 [29] , our results provide additional support for the concept that C\EBPβ may contain a nuclear export sequence, and that alterations in the nucleocytoplasmic shuttling of C\EBPβ may affect its transcriptional activity. It is interesting that phosphorylation of C\EBPβ on Ser#$* enhanced nuclear export and decreased transcriptional activity in hepatocytes [31] . Although we observed a 50-70 % decrease in the phosphorylation of C\EBPβ by ceramide, it is possible that this may have occurred on residues other than Ser#$*. Thus we cannot determine whether enhanced nuclear export of C\EBPβ in ceramide-treated adipocytes also requires this specific modification. Alternatively, mechanisms controlling nuclear export of C\EBPβ may differ between TNFα-treated hepatocytes and differentiating preadipocytes. For example, other protein modifications of C\EBPβ might also be involved in regulating its localization. Conjugation of transcription factors with the small ubiquitin-like molecule SUMO-1 is known to regulate their nuclear localization and transcriptional activity [38] . Moreover, at least in yeast, sumoylation (i.e. post-translational modification by SUMO-1 equivalent to that of ubiquitinylation with ubiquitin) might also regulate interactions between centromeric proteins [39] . Intriguingly, C\EBPβ contains a consensus sumoylation sequence in its Nterminal region (Leu-Lys-Ala-Glu) [38] , which raises the possibility that changes in phosphorylation and\or sumoylation of C\EBPβ might affect its centromeric localization, transcriptional activity and rate of nuclear export.
In summary, our data provide a novel perspective on potential molecular mechanisms by which ceramide may regulate the activity of a transcription factor that is involved in adipogenesis and is up-regulated in response to inflammatory cytokines (e.g. TNFα, interleukin-1β and interleukin-6), nerve growth factors, lipopolysaccharide, heavy metals, diabetes and age [14, 40, 41] . Since the activity and localization of C\EBPβ are strongly regulated by phosphorylation, ceramide may have diverse effects on its transcriptional activity, depending upon the subset of kinases and\or phosphatases that may be activated by ceramide in a given cell type.
